005250.KS
Green Cross Holdings Corporation [005250.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
005250.KS Stock Summary
Top 005250.KS Correlated Resources
005250.KS
Top 10 Correlated ETFs
005250.KS
Top 10 Correlated Stocks
005250.KS
005250.KS Financial details
Company Rating
Buy
Market Cap
770.62B
Income
14.3B
Revenue
2080.21B
Book val./share
32352.13
Cash/share
-
Dividend
400
Dividend %
2.32%
Employees
154
Optionable
No
Shortable
Yes
Earnings
13 Feb 2023
P/E
37.89
Forward P/E
-
PEG
-4.31
P/S
0.26
P/B
0.53
P/C
-
P/FCF
-12.22
Quick Ratio
-
Current Ratio
1.34
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
455.21
EPS next Y
-
EPS next Q
-
EPS this Y
-53.62%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.99%
Revenue last 5Y
4.67%
Revenue Q/Q
7.08%
EPS Q/Q
-133.2%
-
-
-
-
SMA20
1.11%
SMA50
3.2%
SMA100
-15.07%
Inst Own
-
Inst Trans
-
ROA
-
ROE
1%
ROC
0.03%
Gross Margin
33%
Oper. Margin
4%
Profit Margin
1%
Payout
88%
Shs Outstand
44.93M
Shs Float
24.4M
-
-
-
-
Target Price
-
52W Range
14950.0-29400.0
52W High
-41.33%
52W Low
+15.38%
RSI
52
Rel Volume
1.39
Avg Volume
52.36K
Volume
72.82K
Perf Week
0.88%
Perf Month
5.18%
Perf Quarter
-9.92%
Perf Half Y
-19.2%
-
-
-
-
Beta
1.19687
-
-
Volatility
116.06%, 385.43%
Prev Close
0.29%
Price
17250
Change
2.07%
005250.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 32.6K | 34.45K | 33.93K | 38.26K | 58.58K | |
| Net income per share | 965.06 | 410.97 | 65.82 | 3.8K | 1.76K | |
| Operating cash flow per share | 3.22K | 837.75 | 170.26 | 848.76 | 3.3K | |
| Free cash flow per share | -1.48K | -2.46K | -3.5K | -2.17K | -1.21K | |
| Cash per share | 6.05K | 6.04K | 4.94K | 11.35K | 12.68K | |
| Book value per share | 18.09K | 17.9K | 18.09K | 20.46K | 32.64K | |
| Tangible book value per share | 29.52K | 29.39K | 30.41K | 30.26K | 43.84K | |
| Share holders equity per share | 18.09K | 17.9K | 18.09K | 20.46K | 32.64K | |
| Interest debt per share | 15.7K | 18.03K | 19.45K | 21.85K | 30.41K | |
| Market cap | 1945.65B | 1071.68B | 941.37B | 1977.1B | 692.83B | |
| Enterprise value | 2368.44B | 1613.35B | 1620.3B | 2487.02B | 1285.26B | |
| P/E ratio | 44.87 | 58.03 | 318.31 | 11.56 | 12.54 | |
| Price to sales ratio | 1.33 | 0.69 | 0.62 | 1.15 | 0.38 | |
| POCF ratio | 13.47 | 28.47 | 123.05 | 51.84 | 6.68 | |
| PFCF ratio | -29.21 | -9.71 | -5.98 | -20.26 | -18.2 | |
| P/B Ratio | 2.39 | 1.33 | 1.16 | 2.15 | 0.68 | |
| PTB ratio | 2.39 | 1.33 | 1.16 | 2.15 | 0.68 | |
| EV to sales | 1.62 | 1.04 | 1.06 | 1.45 | 0.7 | |
| Enterprise value over EBITDA | 19.12 | 15.06 | 17.05 | 8.71 | 6.5 | |
| EV to operating cash flow | 16.39 | 42.86 | 211.79 | 65.21 | 12.39 | |
| EV to free cash flow | -35.56 | -14.62 | -10.3 | -25.49 | -33.76 | |
| Earnings yield | 0.02 | 0.02 | 0 | 0.09 | 0.08 | |
| Free cash flow yield | -0.03 | -0.1 | -0.17 | -0.05 | -0.05 | |
| Debt to equity | 0.55 | 0.52 | 0.58 | 0.24 | 0.42 | |
| Debt to assets | 0.44 | 0.45 | 0.46 | 0.48 | 0.45 | |
| Net debt to EBITDA | 3.41 | 5.06 | 7.15 | 1.78 | 3 | |
| Current ratio | 2.09 | 1.73 | 1.66 | 1.39 | 1.54 | |
| Interest coverage | 8.06 | 2.77 | 1.65 | 2.91 | 3.14 | |
| Income quality | 3.33 | 2.04 | 2.59 | 0.22 | 1.88 | |
| Dividend Yield | 0.01 | 0.02 | 0.02 | 0.01 | 0.05 | |
| Payout ratio | 0.51 | 1.2 | 6.18 | 0.13 | 0.58 | |
| Sales general and administrative to revenue | 0.02 | 0.04 | 0.03 | 0.02 | 0.02 | |
| Research and developement to revenue | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | |
| Intangibles to total assets | 0.04 | 0.05 | 0.05 | 0.1 | 0.15 | |
| Capex to operating cash flow | -1.46 | -3.93 | -21.57 | -3.56 | -1.37 | |
| Capex to revenue | -0.14 | -0.1 | -0.11 | -0.08 | -0.08 | |
| Capex to depreciation | -5.12 | -3.13 | -2.9 | -2.57 | -2.27 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 19.82K | 12.87K | 5.18K | 41.85K | 35.94K | |
| ROIC | 0.06 | 0.02 | 0.01 | 0.03 | 0.03 | |
| Return on tangible assets | 0.02 | 0.01 | 0 | 0.06 | 0.02 | |
| Graham Net | -13.37K | -15.32K | -18.21K | -18.1K | -29.73K | |
| Working capital | 622.28B | 482.8B | 447.31B | 433.03B | 498.95B | |
| Tangible asset value | 1326.51B | 1320.53B | 1366.64B | 1359.56B | 1377.48B | |
| Net current asset value | 70.34B | -30.89B | -143.62B | -31.9B | -161.24B | |
| Invested capital | 0.85 | 0.99 | 1.05 | 1.04 | 0.9 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 186.66B | 166.04B | 155.93B | 161.83B | 155.41B | |
| Average inventory | 492.81B | 460.32B | 471.46B | 489.14B | 498.07B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 73.29 | 54.4 | 50.01 | 49.68 | 44.87 | |
| Days of inventory on hand | 172.06 | 137.9 | 151.26 | 150.15 | 152.68 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 4.98 | 6.71 | 7.3 | 7.35 | 8.14 | |
| Inventory turnover | 2.12 | 2.65 | 2.41 | 2.43 | 2.39 | |
| ROE | 0.05 | 0.02 | 0 | 0.19 | 0.05 | |
| Capex per share | -4.7K | -3.29K | -3.67K | -3.02K | -4.51K |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 10.17K | 11.8K | 16.14K | 16.46K | 17.62K | |
| Net income per share | 31.21 | 448 | 651.21 | -200.74 | 66.65 | |
| Operating cash flow per share | 699.06 | 433.31 | 2.83K | 666.08 | -1.08K | |
| Free cash flow per share | -42.22 | -128.86 | 1.16K | -273.32 | -2.11K | |
| Cash per share | 10.43K | 8.8K | 12.68K | 0 | 0 | |
| Book value per share | 20.59K | 21.26K | 32.64K | 32.11K | 32.35K | |
| Tangible book value per share | 30.34K | 31.72K | 43.84K | 60.99K | 62.15K | |
| Share holders equity per share | 20.59K | 21.26K | 32.64K | 32.11K | 32.35K | |
| Interest debt per share | 23.16K | 21.45K | 29.75K | -348.64 | -34.36 | |
| Market cap | 1532.26B | 1419.88B | 853.08B | 615.85B | 512.16B | |
| Enterprise value | 2146.9B | 2059.03B | 1445.5B | 615.85B | 512.16B | |
| P/E ratio | 273.15 | 17.61 | 10.42 | -24.41 | 61.14 | |
| Price to sales ratio | 3.35 | 2.67 | 1.68 | 1.19 | 0.92 | |
| POCF ratio | 48.78 | 72.81 | 9.58 | 29.43 | -15.06 | |
| PFCF ratio | -807.77 | -244.84 | 23.48 | -71.71 | -7.72 | |
| P/B Ratio | 1.66 | 1.48 | 0.83 | 0.61 | 0.5 | |
| PTB ratio | 1.66 | 1.48 | 0.83 | 0.61 | 0.5 | |
| EV to sales | 4.7 | 3.88 | 2.85 | 1.19 | 0.92 | |
| Enterprise value over EBITDA | 88.77 | 30.04 | 27.33 | -38.93 | 26.32 | |
| EV to operating cash flow | 68.35 | 105.59 | 16.24 | 29.43 | -15.06 | |
| EV to free cash flow | -1.13K | -355.06 | 39.78 | -71.71 | -7.72 | |
| Earnings yield | 0 | 0.01 | 0.02 | -0.01 | 0 | |
| Free cash flow yield | 0 | 0 | 0.04 | -0.01 | -0.13 | |
| Debt to equity | 0.47 | 0.45 | 0.42 | 0 | 0 | |
| Debt to assets | 0.49 | 0.47 | 0.45 | 0.46 | 0.47 | |
| Net debt to EBITDA | 25.41 | 9.32 | 11.2 | 0 | 0 | |
| Current ratio | 1.6 | 1.7 | 1.54 | 1.36 | 1.34 | |
| Interest coverage | 1.91 | 10.92 | -2.61 | -0.9 | -41.62 | |
| Income quality | 22.4 | 0.97 | 4.35 | -3.32 | -16.23 | |
| Dividend Yield | 0.02 | 0 | 0 | 0.05 | 0 | |
| Payout ratio | 20.42 | 0 | 0 | -4.76 | 0.45 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.03 | 0.31 | 0.27 | |
| Research and developement to revenue | 0.06 | 0.08 | 0.1 | 0 | 0 | |
| Intangibles to total assets | 0.1 | 0.1 | 0.15 | 0 | 0 | |
| Capex to operating cash flow | -1.06 | -1.3 | -0.59 | -1.41 | 0.95 | |
| Capex to revenue | -0.07 | -0.05 | -0.1 | -0.06 | -0.06 | |
| Capex to depreciation | -2.43 | -1.43 | -3.27 | -1.64 | -1.65 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.8K | 14.64K | 21.87K | 12.04K | 6.97K | |
| ROIC | 0.01 | 0.03 | -0.01 | 0 | 0.02 | |
| Return on tangible assets | 0 | 0.01 | 0.01 | 0 | 0 | |
| Graham Net | -19.8K | -20.29K | -29.73K | -51.5K | -54.15K | |
| Working capital | 548.52B | 606.46B | 498.95B | 360.63B | 370.61B | |
| Tangible asset value | 1363.16B | 1427.43B | 1377.48B | 0 | 0 | |
| Net current asset value | -164.51B | -95.26B | -161.24B | -254.06B | -255.92B | |
| Invested capital | 1.12 | 1 | 0.9 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 35.34 | 37.15 | 37.7 | 0 | 0 | |
| Days of inventory on hand | 152.72 | 145.29 | 128.31 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 2.55 | 2.42 | 2.39 | 0 | 0 | |
| Inventory turnover | 0.59 | 0.62 | 0.7 | 0 | 0 | |
| ROE | 0 | 0.02 | 0.02 | -0.01 | 0 | |
| Capex per share | -741.27 | -562.17 | -1.68K | -939.4 | -1.03K |
005250.KS Frequently Asked Questions
What is Green Cross Holdings Corporation stock symbol ?
Green Cross Holdings Corporation is a US stock and trading under the symbol 005250.KS
What is Green Cross Holdings Corporation stock quote today ?
Green Cross Holdings Corporation stock price is $17250 today.
Is Green Cross Holdings Corporation stock public?
Yes, Green Cross Holdings Corporation is a publicly traded company.
Company Profile
- Volume Average 52.36K
- Market Capitalization 770.62B
- Employee 154
- Headquarters Yongin-Si,US
- IPO Date 2000-01-04
-
Website
https://www.greencross.com 
Green Cross Holdings Corporation operates as a biotechnology company. The company provides plasma derivatives, prescription drugs, over the counter drugs, and hunter syndrome drugs; and vaccines for hemorrhagic fever, varicella, hepatitis-B, and flu. It also researches and develops oncology, immunology, and cell therapy products; and offers recombinant protein treatment for hemophilia. The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies. Green Cross Holdings was founded in 1967 and is headquartered in Yongin, South Korea.
